This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of cancer survivors with cancer related cognitive impairment.
Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions
Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years
Non-breast cancer patients exposed to other anticancer therapies within the past 3 years
Washout from investigational interventions is up to the discretion of the Investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.
Presence of brain metastasis
Unwilling to undergo neuropsychological assessments necessary for the study.
Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy.
History of suspected hypersensitivity to riluzole or to any of its excipients.